Saturday, January 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

DARPA Awards ‘Safe Genes’ Contract to Mass Gen

by Global Biodefense Staff
June 6, 2017
Safe Genes: DARPA Gene Editing Program

Credit: DARPA, adapted.

The Defense Advanced Research Projects Agency (DARPA) has awarded a cooperative agreement to Massachusetts General Hospital for research and development supporting the Safe Genes program.

The Safe Genes program aims to deliver novel biological capabilities to facilitate the safe and expedient pursuit of advanced genome editing applications, while also providing the tools and methodologies to mitigate the risk of unintentional consequences or intentional misuse of these technologies.

There are three primary technical focus areas within the Safe Genes program to help bridge the gap between the current technological landscape and the future transformative applications of genome editing tools and engineered organisms. First, researchers will design and develop the genetic circuitry and genome editing machinery for robust, spatial, temporal, and reversible control of genome editing activity in living systems.

The second technical focus area will develop small molecules and/or molecular strategies to provide prophylactic and treatment solutions that prevent or limit genome editing activity and protect the genome integrity of organisms and populations.

Finally, researchers will develop “genetic remediation” strategies that eliminate unwanted engineered genes from a broad range of complex population and environmental contexts to restore systems to functional and genetic baseline states. Overall the program aims to create a layered, modular, and adaptable solution set to access translational applications of genome editing technologies while protecting against intentional or accidental misuse of these tools.

The contract has a ceiling value of $11,000,660. The scope of Massachusetts General Hospital’s work under the Safe Gene program is unspecified.

Work will be performed in Boston, Massachusetts (51 percent); London, United Kingdom (24 percent); Raleigh, North Carolina (8 percent); and Perugia, Italy (17 percent), with an expected completion date of April 2021. Fiscal 2016 funds in the amount of $987,271 are being obligated at time of award.

This was a competitive acquisition and 17 offers were received. The Defense Advanced Research Projects Agency, Arlington, Virginia, is the contracting activity (HR0011-17-2-0042).

Source: Defense.gov, Darpa.mil

Tags: AwardsCRISPRDARPADual Use Research of Concern (DURC)Synthetic Biology

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Killing Anthrax More Quickly with Hot Air Decontamination
CBRNE

Killing Anthrax More Quickly with Hot Air Decontamination

January 4, 2023
DARPA Pursues Advanced Threat-Detection for Crop Defense
Biosecurity

DARPA Pursues Advanced Threat-Detection for Crop Defense

January 3, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC